Vaikom Subramanian Mahadevan

Dr. Vaikom Subramanian Mahadevan

orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 May 2021 in Journal of the American Heart Association
Verified
Journal Article
Open access
PDF file
JCJohn S. Chorba
John S. Chorba
ASAvi M. Shapiro
Avi M. Shapiro
LLLe Le
Le Le
JMJohn Maidens
John Maidens
JPJohn Prince
John Prince
JTJames D. Thomas
James D. Thomas
Background: Clinicians vary markedly in their ability to detect murmurs during cardiac auscultation and identify the underlying pathological features. Deep learning approaches have shown promise in medicine by transforming collected data into clinically significant information. The objective of this research is to assess the performance of a deep learning algorithm to detect murmurs and clinically significant valvular heart disease using recordings from a commercial digital stethoscope platform. Methods and Results: Using >34 hours of previously acquired and annotated heart sound recordings, we trained a deep neural network to detect murmurs. To test the algorithm, we enrolled 962 patients in a clinical study and collected recordings at the 4 primary auscultation locations. Ground truth was established using patient echocardiograms and annotations by 3 expert cardiologists. Algorithm performance for detecting murmurs has sensitivity and specificity of 76.3% and 91.4%, respectively. By omitting softer murmurs, those with grade 1 intensity, sensitivity increased to 90.0%. Application of the algorithm at the appropriate anatomic auscultation location detected moderate‐to‐severe or greater aortic stenosis, with sensitivity of 93.2% and specificity of 86.0%, and moderate‐to‐severe or greater mitral regurgitation, with sensitivity of 66.2% and specificity of 94.6%. Conclusions: The deep learning algorithm’s ability to detect murmurs and clinically significant aortic stenosis and mitral regurgitation is comparable to expert cardiologists based on the annotated subset of our database. The findings suggest that such algorithms would have utility as front‐line clinical support tools to aid clinicians in screening for cardiac murmurs caused by valvular heart disease. Registration: URL: https://clinicaltrials.gov ; Unique Identifier: NCT03458806.

6 June 2024 in JACC: Cardiovascular Imaging
Verified
Journal Article
Closed access
GTGilbert H.L. Tang
Gilbert H.L. Tang
SZSyed Zaid
Syed Zaid
RHRebecca T Hahn
Rebecca T Hahn
VAVratika Aggarwal
Vratika Aggarwal
MAMohamad Alkhouli
Mohamad Alkhouli
RBRalph Stephan von Bardeleben
Ralph Stephan von Bardeleben

14 October 2024 in JACC: Cardiovascular Interventions
Verified
Journal Article
Closed access
VDV. Vivian Dimas
V. Vivian Dimas
VBVasilis Babaliaros
Vasilis Babaliaros
DKDennis Kim
Dennis Kim
DLD. Scott Lim
D. Scott Lim
GMGareth Morgan
Gareth Morgan
SSShabana Shahanavaz
Shabana Shahanavaz

23 September 2014 in International Journal of Cardiology
Verified
Journal Article
Open access
PDF file
ITI.P. Temple
I.P. Temple
OMO. Monfredi
O. Monfredi
GQG. Quigley
G. Quigley
HSHans Gerhard Schneider
Hans Gerhard Schneider
MZMin Zi
Min Zi
GHG. Hart
G. Hart
Pulmonary arterial hypertension (PAH) is a disease characterised by raised pulmonary vascular resistance. It has a poor prognosis typically resulting in progressive right ventricular failure and death. Treatment in PAH has advanced rapidly over the past decade with the use of Ca2+ channel blockers, prostanoids, endothelin receptor antagonists (ERAs) and phosphodiesterase-5 inhibitors [ 1 x [1] Galie, N., Hoeper, M.M., Humbert, M., Torbicki, A., Vachiery, J.L., Barbera, J.A. et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J. Oct 2009; 30: 2493–2537 Crossref | PubMed | Scopus (2458) | Google Scholar See all References ] [1] . PAH often has an insidious onset, which means that diagnosis and treatment are usually not begun until the disease is advanced. Recent studies have looked at patients with less severe disease (World Health Organisation (WHO) class II), and have shown that early initiation of therapy can delay the progression of the disease [ 2 x [2] Galie, N., Rubin, L., Hoeper, M., Jansa, P., Al-Hiti, H., Meyer, G. et al. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. Lancet. 2008; 371: 2093–2100 Abstract | Full Text | Full Text PDF | PubMed | Scopus (645) | Google Scholar See all References ] [2] .

1 November 2011 in The American Journal of Cardiology
Verified
Journal Article
Open access
OMOliver Monfredi
Oliver Monfredi
LGLinda Griffiths
Linda Griffiths
BCBernard Clarke
Bernard Clarke
VMVaikom Subramanian Mahadevan
Vaikom Subramanian Mahadevan
The dual endothelin receptor antagonist, bosentan, has been shown to be well tolerated and effective in improving pulmonary arterial hypertension (PAH) symptoms in patients with Eisenmenger syndrome but data from longer-term studies are lacking. The aim of this study was to retrospectively analyze the long-term efficacy and safety of bosentan in adults with PAH secondary to congenital heart disease (PAH-CHD). Prospectively collected data from adult patients with PAH-CHD (with and without Down syndrome) initiated on bosentan from October 2007 through June 2010 were analyzed. Parameters measured before bosentan initiation (62.5 mg 2 times/day for 4 weeks titrated to 125 mg 2 times/day) and at each follow-up (1 month and 3, 6, 9, 12, 18, and 24 months) included exercise capacity (6-minute walk distance [6MWD]), pretest oxygen saturation, liver enzymes, and hemoglobin. Data were analyzed from 39 patients with PAH-CHD (10 with Down syndrome) who had received ≥ 1 dose of bosentan (mean duration of therapy 2.1 ± 1.5 years). A significant (p < 0.0001) average improvement in 6MWD of 54 m over a 2-year period in patients with PAH-CHD without Down syndrome was observed. Men patients had a 6MWD of 33 m greater than women (p < 0.01). In all patients, oxygen saturation, liver enzymes, and hemoglobin levels remained stable. There were no discontinuations from bosentan owing to adverse events. In conclusion, patients with PAH-CHD without Down syndrome gain long-term symptomatic benefits in exercise capacity after bosentan treatment. Men seem to benefit more on bosentan treatment. Bosentan appears to be well tolerated in patients with PAH-CHD with or without Down syndrome.

1 August 2020 in IJC Heart & Vasculature
Verified
Journal Article
Open access
LCLara Curran
Lara Curran
HAHarsh Agrawal
Harsh Agrawal
KKKimberly Kallianos
Kimberly Kallianos
AKAhmed Kheiwa
Ahmed Kheiwa
SLShezhang Lin
Shezhang Lin
VMVaikom Subramanian Mahadevan
Vaikom Subramanian Mahadevan
To evaluate the predictive value of Computed Tomography Angiography (CTA) measurements of the RVOT for transcatheter valve sizing. Transcatheter pulmonary valve replacement (TPVR) provides an alternative to surgery in patients with right ventricular outflow tract (RVOT) dysfunction. We studied 18 patients who underwent catheterization for potential TPVR to determine whether CT imaging can be used to accurately predict implant size. Cases were grouped by RVOT characteristics: native or transannular patch (n = 8), conduit (n = 5) or bioprosthetic valve (n = 5). TPVR was undertaken in 14/18 cases, after balloon-sizing was used to confirm suitability and select implant size. Retrospective CT measurements of the RVOT (circumference-derived (Dcirc) and area-derived (Darea) diameters) were obtained at the level of the annulus, bioprosthesis or conduit. Using manufacturer sizing guidance, a valve size was generated and a predicted valve category assigned: (1) 29 mm. Predicted and implanted valves were compared for inter-rater agreement using Cohen’s kappa coefficient. The median age of patients was 37 years old (IQR: 30–49); 55% were male. Diagnoses included: Tetralogy of Fallot (12/18), d-Transposition repair (3/18), congenital pulmonary stenosis (2/18) and carcinoid heart disease (1/18). Measurements of Darea (κ = 0.697, p < 0.01) and Dcirc (κ = 0.540, p < 0.01) were good predictors of implanted valve size. When patients with RVOT conduits were excluded, the predictive accuracy improved for Darea (κ = 0.882, p < 0.01) and Dcirc (κ = 0.882, p < 0.01). CT measurement of the RVOT, using Darea or Dcirc, can predict prosthetic valve sizing in TPVR. These measurements are less predictive in patients with conduits, compared to those with a native RVOT or pulmonic bioprosthesis. We studied 18 patients who underwent catheterization for TPVR to determine whether CT imaging could be used to accurately predict implant size. Retrospective RVOT measurements were used to generate a predicted valve size, which was compared with implanted valve size for inter-rater agreement. Measurements of Darea (κ = 0.697, p < 0.01) and Dcirc (κ = 0.540, p < 0.01) were good predictors of implanted valve size. When cases with RVOT conduits were excluded, the predictive accuracy improved for Darea (κ = 0.882, p < 0.01) and Dcirc (κ = 0.882, p < 0.01). CT measurement of the RVOT can accurately predict prosthetic valve sizing in TPVR. These measurements are less predictive in patients with conduits.